Valneva (VALN) Competitors $11.64 +0.45 (+4.02%) As of 08/22/2025 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. TLX, PTCT, LNTH, APLS, MLTX, PTGX, MIRM, MENS, MTSR, and BHCShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Telix Pharmaceuticals (TLX), PTC Therapeutics (PTCT), Lantheus (LNTH), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), Metsera (MTSR), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors Telix Pharmaceuticals PTC Therapeutics Lantheus Apellis Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Jyong Biotech Metsera Bausch Health Cos Telix Pharmaceuticals (NASDAQ:TLX) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Which has stronger earnings & valuation, TLX or VALN? Telix Pharmaceuticals has higher revenue and earnings than Valneva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M8.17$32.93MN/AN/AValneva$183.52M5.40-$13.25M-$0.98-11.88 Does the media prefer TLX or VALN? In the previous week, Telix Pharmaceuticals had 10 more articles in the media than Valneva. MarketBeat recorded 30 mentions for Telix Pharmaceuticals and 20 mentions for Valneva. Valneva's average media sentiment score of 0.73 beat Telix Pharmaceuticals' score of 0.35 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Valneva 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TLX or VALN? Telix Pharmaceuticals currently has a consensus price target of $22.33, suggesting a potential upside of 78.95%. Valneva has a consensus price target of $16.00, suggesting a potential upside of 37.46%. Given Telix Pharmaceuticals' higher possible upside, equities analysts plainly believe Telix Pharmaceuticals is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of TLX or VALN? 11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is TLX or VALN more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Valneva's net margin of -33.87%. Telix Pharmaceuticals' return on equity of 0.00% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Valneva -33.87%-34.78%-13.43% SummaryTelix Pharmaceuticals beats Valneva on 9 of the 12 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$952.20M$10.77B$5.75B$9.61BDividend YieldN/A1.87%4.41%4.10%P/E Ratio-11.8821.2531.2226.05Price / Sales5.4029.39434.78103.68Price / Cash114.5224.5537.7358.48Price / Book4.673.519.536.61Net Income-$13.25M$211.77M$3.26B$265.65M7 Day Performance0.95%4.44%2.14%2.03%1 Month Performance59.02%8.85%2.83%-0.30%1 Year Performance50.00%-9.03%30.64%19.06% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.3832 of 5 stars$11.64+4.0%$16.00+37.5%+52.2%$952.20M$183.52M-11.88700Trending NewsAnalyst ForecastAnalyst RevisionGap UpTLXTelix PharmaceuticalsN/A$11.90+3.1%$22.33+87.7%N/A$3.91B$516.72M0.00N/ATrending NewsAnalyst RevisionHigh Trading VolumePTCTPTC Therapeutics4.4374 of 5 stars$49.80+2.0%$70.15+40.9%+51.3%$3.88B$1.76B7.141,410Trending NewsAnalyst ForecastAnalyst RevisionLNTHLantheus4.7604 of 5 stars$55.97+3.3%$105.50+88.5%-43.1%$3.68B$1.52B14.89700Trending NewsInsider TradeAnalyst RevisionAPLSApellis Pharmaceuticals4.1615 of 5 stars$27.35-1.4%$34.12+24.7%-28.5%$3.50B$781.37M-15.03770News CoverageInsider TradeShort Interest ↑MLTXMoonLake Immunotherapeutics1.6262 of 5 stars$53.73-1.2%$74.43+38.5%+15.0%$3.49BN/A-19.332PTGXProtagonist Therapeutics1.8064 of 5 stars$56.21+0.2%$67.20+19.6%+38.7%$3.49B$434.43M80.30120Positive NewsMIRMMirum Pharmaceuticals3.503 of 5 stars$66.68-1.8%$74.13+11.2%+74.5%$3.41B$336.89M-55.11140News CoveragePositive NewsMENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.40BN/A0.0031News CoverageMTSRMetseraN/A$32.39+4.0%$55.00+69.8%N/A$3.27BN/A0.0081News CoverageBHCBausch Health Cos4.2192 of 5 stars$8.02-3.8%$9.00+12.2%+29.7%$3.09B$9.63B30.8520,700Trending NewsAnalyst Revision Related Companies and Tools Related Companies TLX Alternatives PTCT Alternatives LNTH Alternatives APLS Alternatives MLTX Alternatives PTGX Alternatives MIRM Alternatives MENS Alternatives MTSR Alternatives BHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access